The Future of Oncology: Multi-Cancer Early Detection and the New Prevention Paradigm
- 15 oct
- 2 Min. de lectura
A profound shift is underway in oncology, moving beyond traditional single-cancer screening methods like mammograms and colonoscopies toward Multi-Cancer Early Detection (MCED). This transformative approach promises to catch cancers—even aggressive types like pancreatic, liver, and lung cancers—before symptoms appear and before the disease spreads, offering hope for improved survival rates.
Cancer remains the second leading cause of death, and the prevalence of aggressive cancers is rising, with pancreatic and liver cancers expected to surpass breast and colorectal cancers as leading causes of death by 2040. These cancers are historically diagnosed late, leading to limited treatment options and poorer outcomes.
MCED changes the game by using a single blood sample—a process known as liquid biopsy—to detect multiple biological signals, including genomic, epigenomic, and proteomic markers, that may indicate cancer presence.
A leading example of this innovation is the Cancerguard™ test, developed by Exact Sciences. This next-generation test evaluates both DNA methylation and protein biomarkers, making it the only MCED test currently on the market that analyzes both circulating tumor DNA and cancer-associated proteins.
In development studies, the Cancerguard test showed promising results, demonstrating 64% overall sensitivity and 67.8% sensitivity for six lethal cancers: pancreatic, esophageal, liver, lung, stomach, and ovarian. Crucially, it maintained high specificity at 97.4%, which helps minimize false positives that could lead to unnecessary procedures.
It is important to note that the Cancerguard test is intended for adults aged 50–84 with no known cancer diagnosis in the last three years. It is designed to complement existing routine screening—not replace them—and is currently not cleared or approved by the U.S. Food and Drug Administration (FDA). A positive result requires further clinical evaluation and follow-up imaging.
The future of MCED looks highly promising, driven by cutting-edge advancements such as Artificial Intelligence (AI) and nanotechnology. AI models, such as Harvard Medical School’s "Chief," have demonstrated accuracy rates as high as 94% in detecting multiple cancer types.
The market reflects this excitement, with the global MCED market valued at $935.9 million in 2023 and projected to surge to $5,153.5 million by 2034, representing a Compound Annual Growth Rate (CAGR) of 16.3%. North America currently holds the largest market share, with the U.S. accounting for approximately 30% of global MCED revenue in 2024.
Despite the potential to revolutionize prevention, widespread adoption faces hurdles, primarily the high cost of advanced diagnostic tests and the evolving regulatory landscape. Continued innovation to lower costs and secure regulatory approvals is crucial to unlock the full potential of this technology.
🔖 Sources
